Tedibar

Ahmedabad, India Founded: 2023 • Age: 3 yrs Listed
Offers gentle, moisturizing baby bathing bars and washes for sensitive skin care.
Request Access
Report Incorrect Data
Page last updated

About Tedibar

Tedibar is a publicly listed company based in Ahmedabad (India) founded in 2023. It offers gentle, moisturizing baby bathing bars and washes for sensitive skin care. It operates on a B2C and D2C model. The company has 15,615 employees. Its Indian entity Torrent Pharmaceuticals Ltd reported revenue of ₹19,181 Cr. Tedibar offers products and services including Tedibar Bathing Bar, Tedibar Body Wash, Atogla Lotion, and Spoo Anti Seborrheic Shampoo. Its focus areas include Personal Care, Baby Care and Skin Care Products. Its competitors include Mother Sparsh Baby Care, Herby Angel and Tiny Mighty; 3 of its 3 listed competitors have raised funding.

Company details

Tedibar specializes in pediatrician-recommended skin care products for babies, including moisturizing bathing bars and washes that are soap-free and pH-balanced to prevent irritation. These items are dermatologically tested and designed for daily use, helping maintain hydration and skin health. Based in India, Tedibar serves parents seeking safe options for newborns and children with sensitive skin, emphasizing gentle formulas trusted by medical professionals.

Operational Areas
Consumer → Beauty & Personal Care Products
Key Metrics
  • Market Cap
    ₹1,75,920 Cr

    TORNTPHARM · NSE

  • Share Price
    ₹4,557.00

    -1.47% today

  • Revenue
    ₹19,274 Cr

    FY 2025-26 · +67.4% YoY

  • EBITDA
    ₹4,470 Cr

    Margin 23.2%

  • Net Profit
    ₹2,192 Cr

    FY 2025-26 · +14.4% YoY

  • P/E (TTM)
    77.1x

    P/B 20.5x

  • ROE
    26.8%

    ROCE 18.3%

  • Debt / Equity
    1.14

    Interest cover 11.5x

  • Employee Count
    15,615

Products & Services of Tedibar

Tedibar offers a comprehensive portfolio of products and services, including Tedibar Bathing Bar, Tedibar Body Wash, Atogla Lotion, and Spoo Anti Seborrheic Shampoo.

Tedibar Bathing Bar
Baby Skin Care

Moisturizing bar for gentle, pH-balanced cleansing of baby's skin.

Tedibar Body Wash
Baby Skin Care

Soap-free wash to hydrate and protect sensitive baby skin.

Atogla Lotion
Baby Skin Care

Moisturizing lotion with oat lipids for baby's dry skin relief.

Spoo Anti Seborrheic Shampoo
Baby Hair Care

Shampoo to treat seborrheic conditions on baby's scalp gently.

Apps and channels of Tedibar

its YouTube channel Tedibar has 7.52K subscribers and 30 videos.

Tedibar
YouTube 7.52K subscribers 30 videos Music
Open channel

Videos from Tedibar

The most watched videos on Tedibar's YouTube channel, Tedibar (7.52K subscribers). Click a video to play it here.

Tedibar - Bath Time Is We Time | Fun Bath Time Song
7.5M views
Tedibar - #1* Pediatrician Prescribed Moisturising Bar | Go soap-free | Telugu | 30 Sec
2.5M views
Tedibar - #1* Pediatrician Prescribed Moisturising Bar | Go soap-free | Tamil | 30 Sec
2.3M views
Say Hello to Soft-Soft Skin with the All-new Tedibar CeraMax Bathing Bar
2.1M views

More on Tedibar.

Board of directors of Torrent Pharmaceuticals Ltd (Tedibar)

Torrent Pharmaceuticals Ltd is the primary company behind Tedibar. The board of Torrent Pharmaceuticals Ltd currently have 7 directors; the longest-serving is Samir Uttamlal Mehta, appointed in 2010. 23 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Samir Uttamlal Mehta
DIN 00061903
Managing Director01 Aug 201016 yrs 2 moTorrent Pharmaceuticals Ltd
Ameera Sushil Shah
DIN 00208095
Director02 Aug 20188 yrs 2 moTorrent Pharmaceuticals Ltd
Nayantara Bali
DIN 03570657
Director07 Mar 20197 yrs 7 moTorrent Pharmaceuticals Ltd
Manish Mahendra Choksi
DIN 00026496
Director29 Jul 20224 yrs 3 moTorrent Pharmaceuticals Ltd
Nikhil Khattau Nirvan
DIN 00017880
Director01 Oct 20233 yrsTorrent Pharmaceuticals Ltd
Jinal Sudhirbhai Mehta
DIN 02685284
Director24 May 20242 yrs 5 moTorrent Pharmaceuticals Ltd
Aman Samir Mehta
DIN 08174906
Managing Director31 Jul 20251 yr 2 moTorrent Pharmaceuticals Ltd

IPO & Listings of Tedibar

Tedibar is a publicly listed company on the NSE with ticker symbol TORNTPHARM in India, operating in the Pharmaceuticals sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: TORNTPHARM
  • Listed entityTorrent Pharmaceuticals Ltd
  • Exchange sectorPharmaceuticals

Financials of Tedibar

Exchange-reported figures of Torrent Pharmaceuticals Ltd, the listed company behind Tedibar (NSE: TORNTPHARM).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹19,274 Cr
+67.4% YoY
EBITDA
₹4,470 Cr
+20.9% YoY
Profit After Tax
₹2,192 Cr
+14.4% YoY
Net Worth
₹8,388 Cr
+10.5% YoY
Total Assets
₹33,483 Cr
+196.1% YoY
Total Debt
₹15,026 Cr
+369.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue19,27411,51610,7289,6208,5088,0057,939
Revenue growth+67.4%+7.4%+11.5%+13.1%+6.3%+0.8%-
EBITDA4,4703,6973,3682,8421,9472,4802,170
EBITDA margin+23.2%+32.1%+31.4%+29.5%+22.9%+31.0%+27.3%
Profit before tax2,8722,6732,3521,8471,2261,5261,187
Net profit2,1921,9161,5811,2181,0761,2401,002
Net profit margin+11.4%+16.6%+14.7%+12.7%+12.7%+15.5%+12.6%
EPS (₹)63.9256.4748.9436.7945.9273.9760.55
Balance sheet
Total assets33,48311,30911,33311,98210,40111,09411,065
Net worth8,3887,5916,8566,1985,9535,8374,823
Total debt15,0263,2024,0225,3694,0704,8745,784
Cash & bank1,165579839571403604667
Net working capital3,3672,6582,3992,5302,4762,4022,034
Cash flow
Cash from operations3,0232,5853,2662,3681,8032,0051,393
Cash from investing(12,630)(549)(160)(2,335)(196)(444)229
Cash from financing10,151(2,298)(2,780)77.36(1,781)(1,651)(1,549)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,9794,9214,1973,3033,3023,1782,9592,809
Revenue growth (YoY)+50.8%+54.9%+41.8%+17.6%+14.3%+11.2%--
Other income(10.00)(12.00)(17.00)(13.00)(27.00)(37.00)(18.00)33.00
EBITDA1,6561,6431,2901,0781,0701,032940914
EBITDA margin+33.8%+34.0%+31.3%+33.2%+33.0%+33.0%+32.3%+33.1%
Depreciation609593508206204201201199
Interest30030523645.0048.0056.0056.0057.00
Profit before tax737733529814791738665691
Tax203167165179200190167188
Net profit534566364635591548498503
EPS (₹)14.0514.8711.5118.7717.4516.1914.7114.88
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10,7139,6838,5337,6956,7426,4516,168
Revenue growth+10.6%+13.5%+10.9%+14.1%+4.5%+4.6%-
EBITDA3,9833,5522,8892,4652,1012,1921,917
EBITDA margin+37.2%+36.7%+33.9%+32.0%+31.2%+34.0%+31.1%
Profit before tax2,8972,6101,9171,5771,4661,3661,117
Net profit2,2131,8921,3421,0239851,125914
Net profit margin+20.7%+19.5%+15.7%+13.3%+14.6%+17.4%+14.8%
EPS (₹)64.7555.7840.1031.0658.5867.2355.45
Balance sheet
Total assets23,18210,57410,46511,2989,91110,63510,667
Net worth8,4527,5926,8296,4566,3456,0305,121
Total debt14,2772,6293,3444,5753,3484,4045,294
Cash & bank82.9811010914869.4666.42391
Net working capital2,8972,7972,3452,5992,7012,8772,602
Cash flow
Cash from operations2,7312,5742,8932,2652,1401,5731,580
Cash from investing(12,990)(470)(296)(2,326)(160)(316)269
Cash from financing10,225(2,104)(2,578)80.74(1,977)(1,581)(1,555)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,1454,1583,4452,5992,7622,6162,4332,377
Revenue growth (YoY)+50.1%+58.9%+41.6%+9.3%+13.5%+7.3%--
Other income(11.00)(21.00)(30.00)(8.00)(27.00)(5.00)15.003.00
Total expenses2,5842,6062,2831,6091,7031,6371,5891,490
EBITDA1,5611,5521,1629901,059979844887
EBITDA margin+38.4%+38.1%+34.4%+38.9%+39.1%+38.1%+35.4%+38.1%
Depreciation587575490191189187190191
Interest28729322634.0037.0045.0047.0048.00
Profit before tax676663416757806742622651
Tax178171107180209191148166

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Oct 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,9794,9214,1973,3033,3023,1782,9592,809
Revenue growth (YoY)+50.8%+54.9%+41.8%+17.6%+14.3%+11.2%--
Other income(10.00)(12.00)(17.00)(13.00)(27.00)(37.00)(18.00)33.00
EBITDA1,6561,6431,2901,0781,0701,032940914
EBITDA margin+33.8%+34.0%+31.3%+33.2%+33.0%+33.0%+32.3%+33.1%
Depreciation609593508206204201201199
Interest30030523645.0048.0056.0056.0057.00
Profit before tax737733529814791738665691
Tax203167165179200190167188
Net profit534566364635591548498503
EPS (₹)14.0514.8711.5118.7717.4516.1914.7114.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue19,27411,51610,7289,6208,5088,0057,939
Revenue growth+67.4%+7.4%+11.5%+13.1%+6.3%+0.8%-
Other income(93.58)23.2714645.1419756.91121
Total expenses14,8057,8197,3606,7786,5615,5245,769
Employee cost2,6712,2031,9841,6781,5261,4401,429
EBITDA4,4703,6973,3682,8421,9472,4802,170
EBITDA margin+23.2%+32.1%+31.4%+29.5%+22.9%+31.0%+27.3%
Depreciation1,119795808707662658654
Interest385252354333255353451
Profit before tax2,8722,6732,3521,8471,2261,5261,187
Tax734762696602449274162
Net profit2,1921,9161,5811,2181,0761,2401,002
Net profit margin+11.4%+16.6%+14.7%+12.7%+12.7%+15.5%+12.6%
EPS (₹)63.9256.4748.9436.7945.9273.9760.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16916916916984.6284.6284.62
Reserves & surplus8,2197,4216,6876,0295,8685,7534,739
Shareholders' funds (net worth)8,3887,5916,8566,1985,9535,8374,823
Minority interest9,1960.000.000.000.000.000.00
Secured loans12,6842,2263,1504,5303,2954,3325,180
Unsecured loans2,342976872839775542605
Total debt15,0263,2024,0225,3694,0704,8745,784
Total liabilities33,48311,30911,33311,98210,40111,09411,065
Assets
Gross block40,42614,04113,48512,81210,72810,51210,334
Net block33,1917,9478,1388,1216,4237,0657,533
Capital work in progress641478361765630889712
Investments9481561731992261812.11
Inventories3,1382,5412,2792,2302,4622,6812,148
Sundry debtors3,0311,8661,8441,9441,6321,5231,649
Cash & bank balances1,165579839571403604667
Loans & advances1,192523508413483574515
Total current assets8,5265,5105,4705,1584,9815,3824,979
Total current liabilities5,1592,8523,0722,6282,5052,9812,945
Net working capital3,3672,6582,3992,5302,4762,4022,034
Total assets33,48311,30911,33311,98210,40111,09411,065
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash573835509398573662589
Net cash from operating activities3,0232,5853,2662,3681,8032,0051,393
Net cash from investing activities(12,630)(549)(160)(2,335)(196)(444)229
Net cash from financing activities10,151(2,298)(2,780)77.36(1,781)(1,651)(1,549)
Net change in cash544(262)327110(174)(89.26)73.06
Closing cash1,165579839571403604667
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+67.4%+7.4%+11.5%+13.1%+6.3%+0.8%-
EBITDA growth+20.9%+9.8%+18.5%+46.0%-21.5%+14.3%-
PBT growth+7.5%+13.6%+27.3%+50.7%-19.7%+28.6%+111.3%
Net income growth+14.4%+21.2%+29.9%+13.1%-13.2%+23.7%-
Revenue CAGR (3Y)+26.1%+10.6%+10.3%+6.6%+3.5%+10.4%+10.9%
EBITDA CAGR (3Y)+16.3%+23.8%+10.7%+9.4%+6.2%+22.5%+16.4%
Profitability & leverage
Net income margin+11.1%+16.6%+15.4%+12.9%+9.1%+15.6%+12.9%
Return on capital employed+18.3%+25.8%+23.2%+19.5%+18.2%+17.0%+14.8%
Return on net worth+26.8%+26.5%+25.4%+20.5%+18.3%+23.5%+21.5%
Debt / equity1.140.500.720.780.761.001.24
Long-term debt / equity0.820.210.320.390.430.590.75
Interest cover11.498.6913.8115.6119.8619.3729.73
Efficiency & per share
Fixed asset turnover0.710.840.820.820.800.770.78
Inventory turnover6.794.784.764.103.313.313.89
Debtors turnover7.876.215.665.385.395.055.15
EPS (₹)63.9256.4748.9436.7945.9273.9760.55
Dividend per share (₹)38.0032.0028.0022.0048.0035.0032.00
Book value per share (₹)247.84224.27202.57183.13351.75344.90284.99
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,1454,1583,4452,5992,7622,6162,4332,377
Revenue growth (YoY)+50.1%+58.9%+41.6%+9.3%+13.5%+7.3%--
Other income(11.00)(21.00)(30.00)(8.00)(27.00)(5.00)15.003.00
Total expenses2,5842,6062,2831,6091,7031,6371,5891,490
EBITDA1,5611,5521,1629901,059979844887
EBITDA margin+38.4%+38.1%+34.4%+38.9%+39.1%+38.1%+35.4%+38.1%
Depreciation587575490191189187190191
Interest28729322634.0037.0045.0047.0048.00
Profit before tax676663416757806742622651
Tax178171107180209191148166
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10,7139,6838,5337,6956,7426,4516,168
Revenue growth+10.6%+13.5%+10.9%+14.1%+4.5%+4.6%-
Other income17.9231.5091.3681.88204118237
Total expenses6,7306,1325,6445,2304,6424,2594,251
Employee cost1,8791,6361,4511,2511,0981,0971,062
EBITDA3,9833,5522,8892,4652,1012,1921,917
EBITDA margin+37.2%+36.7%+33.9%+32.0%+31.2%+34.0%+31.1%
Depreciation764759761672602610607
Interest341213303298236334430
Profit before tax2,8972,6101,9171,5771,4661,3661,117
Tax705722559526475228178
Net profit2,2131,8921,3421,0239851,125914
Net profit margin+20.7%+19.5%+15.7%+13.3%+14.6%+17.4%+14.8%
EPS (₹)64.7555.7840.1031.0658.5867.2355.45
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16916916916984.6284.6284.62
Reserves & surplus8,2837,4236,6606,2876,2615,9455,036
Shareholders' funds (net worth)8,4527,5926,8296,4566,3456,0305,121
Secured loans12,4942,0552,9834,3663,1434,1854,991
Unsecured loans1,782574361210204219303
Total debt14,2772,6293,3444,5753,3484,4045,294
Total liabilities23,18210,57410,46511,2989,91110,63510,667
Assets
Gross block13,85713,30113,00012,36710,0029,9539,806
Net block7,3707,5547,9867,9726,2516,7417,198
Capital work in progress420402226698568588536
Investments13,172523463361368314135
Inventories1,5261,5611,5661,6021,7971,9121,508
Sundry debtors2,6412,1711,5721,7291,5411,5441,509
Cash & bank balances82.9811010914869.4666.42391
Loans & advances514395354292342480412
Total current assets4,7644,2373,6003,7713,7494,0033,819
Total current liabilities1,8671,4401,2551,1721,0481,1261,218
Net working capital2,8972,7972,3452,5992,7012,8772,602
Total assets23,18210,57410,46511,2989,91110,63510,667
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10510585.4065.0061.8738692.61
Net cash from operating activities2,7312,5742,8932,2652,1401,5731,580
Net cash from investing activities(12,990)(470)(296)(2,326)(160)(316)269
Net cash from financing activities10,225(2,104)(2,578)80.74(1,977)(1,581)(1,555)
Net change in cash(34.14)(0.05)19.4620.403.13(325)294
Closing cash82.9811010914869.4666.42391
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.6%+13.5%+10.9%+14.1%+4.5%+4.6%-
EBITDA growth+12.2%+22.9%+17.2%+17.4%-4.2%+14.3%-
PBT growth+11.0%+36.2%+21.5%+7.6%+7.3%+22.3%+19.4%
Net income growth+16.9%+41.0%+31.2%+3.9%-12.5%+23.1%-
Revenue CAGR (3Y)+11.7%+12.8%+9.8%+7.7%+5.4%+15.0%+10.7%
EBITDA CAGR (3Y)+17.3%+19.1%+9.7%+8.7%+9.2%+34.2%+19.4%
Profitability & leverage
Net income margin+20.5%+19.5%+15.9%+13.7%+14.7%+17.6%+15.2%
Return on capital employed+19.2%+26.8%+20.4%+17.7%+16.6%+16.0%+14.4%
Return on net worth+27.3%+26.2%+20.4%+16.4%+16.0%+20.4%+18.5%
Debt / equity1.050.410.600.620.630.871.08
Long-term debt / equity0.790.190.300.340.400.540.68
Interest cover10.597.6414.2416.6015.7721.1232.85
Efficiency & per share
Fixed asset turnover0.790.740.670.690.680.650.64
Inventory turnover6.946.195.394.533.643.774.30
Debtors turnover4.455.175.174.714.374.234.31
EPS (₹)64.7555.7840.1031.0658.5867.2355.45
Dividend per share (₹)38.0032.0028.0022.0048.0035.0032.00
Book value per share (₹)249.72224.32201.76190.75374.94356.30302.59

Competitors of Tedibar

Tedibar has 3 listed competitors in our database, 3 of them funded. They include Mother Sparsh Baby Care, Herby Angel and Tiny Mighty.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Mother Sparsh Baby Care
mothersparsh.com2015Ambala, India$6.85M71
Ayurvedic baby care products are manufactured and distributed.
Herby Angel
herbyangel.com2022Noida, India$2.5M74
Online platform offering ayurvedic personal care products for babies and kids
Tiny Mighty
tinymighty.in2017Ahmedabad, India$567,520
Online brand offering health and personal care products for children and babies
Premium access

Detailed competitors of Tedibar

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Beauty & Personal Care Products

3 companies that operate in the same segment as Tedibar (Beauty & Personal Care Products) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
FirstCry
Online platform offering a wide range of baby, kids, and maternity products
2010Pune, Maharashtra, IndiaUSD 513.39 MUSD 911.07 M3,752
Bombay Shaving
Online brand offering mens grooming products
2015Gurugram, Haryana, IndiaUSD 52.66 M
Bella Vita
Retailer of perfumes, cosmetics, skincare, and related gift set items
2012Gurugram, Haryana, IndiaUSD 60.63 M
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Tedibar

TORNTPHARM: Rs. 27.78 Crores BSE Block Trade; for ~ 60,000 Shares, at Rs. 4630.00
Exchange Update • 1 day ago
Torrent Pharma: Kotak Institutional Equities on Torrent Pharma Upgrades to Buy, Target Price ₹5,665; Q2 was in line, with strong double-digit base-business growth offset by slower JB Pharma, Germany and higher R&D costs. JB cost synergies reached ₹1.2bn in H1, ahead of schedule, with revenue synergies expected from Q1FY28; forecasts 19% FY26–29 EBITDA CAGR.
Exchange Update • 2 days ago
Torrent Pharma: HSBC on Torrent Pharma Maintains Buy, Target Price ₹5,700; base India sales excluding JB Pharma rose 20% YoY, while JB performance was affected by post-merger integration. Branded-generics growth should support margin expansion, and recovery in JB Pharma's portfolio is the next catalyst.
Exchange Update • 2 days ago
Torrent Pharma: Citi on Torrent Pharma Maintains Buy, Target Price ₹5,860; Q2 was in line, with strong India and Brazil performance offset by temporary JB integration and delayed international deliveries. Management expects gradual JB recovery and improving H2 India growth; around half of the ₹4.5bn synergies are expected in FY27, with the balance in FY28.
Exchange Update • 2 days ago
Torrent Pharma: Jefferies on Torrent Pharma Maintains Buy, Target Price ₹5,900; India base business grew 20% YoY and Brazil delivered 21% constant-currency growth, while US growth remained steady. JB integration is ahead of schedule, with half of cost synergies achieved and revenue synergies expected to support next year's growth.
Exchange Update • 2 days ago
Torrent Pharma: Nomura on Torrent Pharma Maintains Neutral, Target Price ₹5,030; Q2 headline performance slightly missed expectations, but core business remained strong. The company now expects ₹4.5bn of JB Pharma acquisition synergies over two years instead of three, with margins expected to improve slightly in H2FY27 as operations stabilise.
Exchange Update • 2 days ago
TORNTPHARM: Q2 REVENUE 49.79B RUPEES VS 33B (YOY); EST 49.06B
Exchange Update • 5 days ago
TORNTPHARM: Q2 CONS NET PROFIT 5.34B RUPEES VS 5.9B (YOY); EST 5.4B
Exchange Update • 5 days ago
TORNTPHARM: Q2 EBITDA 16.56B RUPEES VS 10.8B (YOY), EST 16.25B; Q2 EBITDA MARGIN 33.26% VS 10.8B% (YOY), EST 33%
Exchange Update • 5 days ago
Torrent Group to build 800-bed hospital & medical college in South Gujarat at ₹910 cr - The HinduBusinessLine
Thehindubusinessline • 1 month ago
Premium access

Complete news archive for Tedibar

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tedibar

Tedibar was founded in 2023.

Tedibar is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.

Tedibar has 15,615 employees.

The primary company behind Tedibar, Torrent Pharmaceuticals Ltd, reported revenue of ₹19,181 Cr for FY 2026, up 67% year on year.

Tedibar specializes in pediatrician-recommended skin care products for babies, including moisturizing bathing bars and washes that are soap-free and pH-balanced to prevent irritation. These items are dermatologically tested and designed for daily use, helping maintain hydration and skin health. Based in India, Tedibar serves parents seeking safe options for newborns and children with sensitive skin, emphasizing gentle formulas trusted by medical professionals.

Tedibar's top competitors include Mother Sparsh Baby Care, Tiny Mighty and Herby Angel.

Tedibar offers Tedibar Bathing Bar, Tedibar Body Wash, Atogla Lotion, and Spoo Anti Seborrheic Shampoo.

Yes, Tedibar is publicly traded on NSE under the ticker symbol TORNTPHARM.

Tedibar operates through Torrent Pharmaceuticals Ltd.

The legal entities of Tedibar currently have 9 directors, including Samir Uttamlal Mehta, Nayantara Bali, Manish Mahendra Choksi and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available